0L35 Stock Overview A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sarepta Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sarepta Therapeutics Historical stock prices Current Share Price US$126.77 52 Week High US$175.10 52 Week Low US$102.30 Beta 0.76 1 Month Change 0.98% 3 Month Change 1.94% 1 Year Change 8.55% 3 Year Change 75.36% 5 Year Change -3.17% Change since IPO 87.59%
Recent News & Updates
Sarepta Therapeutics, Inc. Completes Enrollment in EMERGENE, Phase 3 Clinical Study of SRP-9003 for Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Dec 18
New minor risk - Insider selling Nov 17
New minor risk - Shareholder dilution Nov 07
Third quarter 2024 earnings released: EPS: US$0.35 (vs US$0.46 loss in 3Q 2023) Nov 07
Sarepta Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors Sep 16 See more updates
Sarepta Therapeutics, Inc. Completes Enrollment in EMERGENE, Phase 3 Clinical Study of SRP-9003 for Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Dec 18
New minor risk - Insider selling Nov 17
New minor risk - Shareholder dilution Nov 07
Third quarter 2024 earnings released: EPS: US$0.35 (vs US$0.46 loss in 3Q 2023) Nov 07
Sarepta Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors Sep 16
Executive VP & CFO recently sold US$822k worth of stock Sep 04
Insider recently bought US$5.0m worth of stock Aug 21
New minor risk - Shareholder dilution Aug 08
Second quarter 2024 earnings released: EPS: US$0.068 (vs US$0.27 loss in 2Q 2023) Aug 08
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025 Aug 08
Sarepta Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 29
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above Jun 21
Now 20% undervalued May 09
First quarter 2024 earnings released: EPS: US$0.38 (vs US$5.86 loss in 1Q 2023) May 02 Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024
Full year 2023 earnings released: US$5.80 loss per share (vs US$8.03 loss in FY 2022) Feb 29
Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication Feb 16
Forecast to breakeven in 2024 Feb 14
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 Jan 29
Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Jan 16
Forecast to breakeven in 2024 Jan 09
Forecast to breakeven in 2024 Nov 29
Independent Director recently bought US$3.9m worth of stock Nov 07
Third quarter 2023 earnings released: US$0.46 loss per share (vs US$2.94 loss in 3Q 2022) Nov 02
New major risk - Share price stability Oct 31
Now 45% undervalued after recent price drop Oct 31
Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
Insider recently bought US$3.7m worth of stock Aug 13
Forecast to breakeven in 2024 Aug 04
Second quarter 2023 earnings released: US$0.27 loss per share (vs US$2.65 loss in 2Q 2022) Aug 03
Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Forecast to breakeven in 2024 Jul 14
Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy May 13
No longer forecast to breakeven May 05
First quarter 2023 earnings released: US$5.86 loss per share (vs US$1.20 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$8.03 loss per share (vs US$5.15 loss in FY 2021) Mar 01
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Feb 18
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 11
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 Jan 10
Insufficient new directors Jan 01
Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy Nov 29
Insider recently sold US$94k worth of stock Nov 22
Third quarter 2022 earnings released: US$2.94 loss per share (vs US$0.60 loss in 3Q 2021) Nov 03 Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023
Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 28 Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
Sarepta Therapeutics Submits Biologics License Application for Srp-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy Sep 30
Insider recently bought US$6.0m worth of stock Sep 16
Food and Drug Administration Lifts its Clinical Hold on Sarepta Therapeutics's SRP-5051 for the Treatment of Duchenne Muscular Dystrophy Sep 07
Insider recently bought US$5.0m worth of stock Aug 24
Second quarter 2022 earnings released: US$2.65 loss per share (vs US$1.02 loss in 2Q 2021) Aug 03
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 Aug 03
Sarepta Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 28
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies Jul 08
Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy Jun 24
Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors Jun 03
First quarter 2022 earnings released: US$1.20 loss per share (vs US$2.11 loss in 1Q 2021) May 06
Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022 Apr 26
Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director Apr 07
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 Mar 03
Sarepta Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24
Sarepta Therapeutics, Inc. Announces Topline Results from Part 2 of Study SRP-9001-102 Jan 12
Forecast to breakeven in 2024 Jan 01
Insider recently bought US$300k worth of stock Dec 01
President recently bought US$2.0m worth of stock Nov 18
Third quarter 2021 earnings released: US$0.60 loss per share (vs US$2.50 loss in 3Q 2020) Nov 04
Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA Sep 29
Sarepta Therapeutics, Inc. Raises Product Revenue Guidance for Full Year of 2021 Aug 05
Second quarter 2021 earnings released: US$1.02 loss per share (vs US$1.93 loss in 2Q 2020) Aug 05
Sarepta Therapeutics, Inc. Announces Positive 12-Week Expression and Safety Results from the First 11 Participants Enrolled in Study SRP-9001-103 May 19
First quarter 2021 earnings released: US$2.11 loss per share (vs US$0.23 loss in 1Q 2020) May 07
Sarepta Therapeutics, Inc. Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 May 04
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy May 01
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration Mar 19
Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen) Mar 05
Revenue beats expectations Mar 02
Full year 2020 earnings released: US$7.11 loss per share (vs US$9.71 loss in FY 2019) Mar 02
Sarepta Therapeutics, Inc. Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 Feb 26
Sarepta Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 23
Sarepta Therapeutics, Inc. and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics Jan 14 Shareholder Returns 0L35 GB Biotechs GB Market 7D 0.4% -3.5% 0.3% 1Y 8.5% -23.5% 6.6%
See full shareholder returns
Return vs Industry: 0L35 exceeded the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0L35 matched the UK Market which returned 6.6% over the past year.
Price Volatility Is 0L35's price volatile compared to industry and market? 0L35 volatility 0L35 Average Weekly Movement 6.1% Biotechs Industry Average Movement 9.6% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0L35 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0L35's weekly volatility (6%) has been stable over the past year.
About the Company Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Show more Sarepta Therapeutics, Inc. Fundamentals Summary How do Sarepta Therapeutics's earnings and revenue compare to its market cap? 0L35 fundamental statistics Market cap US$12.06b Earnings (TTM ) US$121.85m Revenue (TTM ) US$1.64b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0L35 income statement (TTM ) Revenue US$1.64b Cost of Revenue US$1.03b Gross Profit US$609.29m Other Expenses US$487.45m Earnings US$121.85m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.28 Gross Margin 37.14% Net Profit Margin 7.43% Debt/Equity Ratio 100.5%
How did 0L35 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 17:38 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sarepta Therapeutics, Inc. is covered by 53 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
Show 50 more analysts 